View Future GrowthBioter 과거 순이익 실적과거 기준 점검 0/6Bioter 의 수입은 연평균 -29.6%의 비율로 감소해 온 반면, Construction 산업은 연평균 44%의 비율로 증가했습니다. 매출은 연평균 29.6%의 비율로 증가해 왔습니다.핵심 정보-29.64%순이익 성장률-29.63%주당순이익(EPS) 성장률Construction 산업 성장률41.75%매출 성장률29.57%자기자본이익률n/a순이익률-1,693.86%최근 순이익 업데이트31 Dec 2024최근 과거 실적 업데이트Reported Earnings • May 05Full year 2024 earnings released: €1.27 loss per share (vs €0.70 loss in FY 2023)Full year 2024 results: €1.27 loss per share (further deteriorated from €0.70 loss in FY 2023). Net loss: €21.3m (loss widened 82% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings.공시 • Apr 28Bioter S.A. to Report Fiscal Year 2023 Results on Apr 29, 2024Bioter S.A. announced that they will report fiscal year 2023 results on Apr 29, 2024Reported Earnings • Oct 04First half 2022 earnings released: €0.30 loss per share (vs €0.22 loss in 1H 2021)First half 2022 results: €0.30 loss per share (further deteriorated from €0.22 loss in 1H 2021). Net loss: €5.10m (loss widened 38% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth.분석 기사 • May 06Robust Earnings May Not Tell The Whole Story For Bioter (ATH:BIOT)Bioter S.A.'s ( ATH:BIOT ) robust recent earnings didn't do much to move the stock. We believe that shareholders have...Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total losses of €12.3m, with losses narrowing by 5.0% from the prior year.모든 업데이트 보기Recent updatesReported Earnings • May 05Full year 2024 earnings released: €1.27 loss per share (vs €0.70 loss in FY 2023)Full year 2024 results: €1.27 loss per share (further deteriorated from €0.70 loss in FY 2023). Net loss: €21.3m (loss widened 82% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings.공시 • Apr 30Bioter S.A., Annual General Meeting, Jul 10, 2025Bioter S.A., Annual General Meeting, Jul 10, 2025.New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.9% average weekly change). Negative equity (-€124m). Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m (€280k revenue, or US$318k). Market cap is less than US$10m (€3.26m market cap, or US$3.70m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).New Risk • Oct 04New major risk - Revenue and earnings growthEarnings have declined by 12% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€11m free cash flow). Share price has been highly volatile over the past 3 months (6.6% average weekly change). Negative equity (-€124m). Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m (€280k revenue, or US$309k). Market cap is less than US$10m (€4.52m market cap, or US$4.98m).공시 • Apr 28Bioter S.A. to Report Fiscal Year 2023 Results on Apr 29, 2024Bioter S.A. announced that they will report fiscal year 2023 results on Apr 29, 2024New Risk • Apr 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€112m). Revenue is less than US$1m (€471k revenue, or US$502k). Market cap is less than US$10m (€4.58m market cap, or US$4.88m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).공시 • Jul 01Bioter S.A., Annual General Meeting, Jul 21, 2023Bioter S.A., Annual General Meeting, Jul 21, 2023, at 09:00 E. Europe Standard Time. Location: 45 Eftichidou str Athens GreeceNew Risk • Jul 01New major risk - Revenue and earnings growthRevenue has declined by 17% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€102m). Revenue has declined by 17% over the past year. Revenue is less than US$1m (€241k revenue, or US$263k). Market cap is less than US$10m (€3.51m market cap, or US$3.83m). Minor Risk Latest financial reports are more than 6 months old (reported June 2022 fiscal period end).Reported Earnings • Oct 04First half 2022 earnings released: €0.30 loss per share (vs €0.22 loss in 1H 2021)First half 2022 results: €0.30 loss per share (further deteriorated from €0.22 loss in 1H 2021). Net loss: €5.10m (loss widened 38% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth.공시 • Sep 01Bioter S.A., Annual General Meeting, Sep 05, 2022Bioter S.A., Annual General Meeting, Sep 05, 2022, at 09:00 E. Europe Standard Time. Location: 45 Eftichidou str Athens GreeceBoard Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.분석 기사 • May 06Robust Earnings May Not Tell The Whole Story For Bioter (ATH:BIOT)Bioter S.A.'s ( ATH:BIOT ) robust recent earnings didn't do much to move the stock. We believe that shareholders have...Is New 90 Day High Low • Jan 04New 90-day high: €0.38The company is up 348% from its price of €0.084 on 06 October 2020. The Greek market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Construction industry, which is up 22% over the same period.공시 • Jan 02Bioter S.A., Annual General Meeting, Jan 11, 2021Bioter S.A., Annual General Meeting, Jan 11, 2021, at 11:00 E. Europe Standard Time. Location: 45 Eftichidou str. Athens United KingdomIs New 90 Day High Low • Dec 16New 90-day high: €0.22The company is up 154% from its price of €0.085 on 17 September 2020. The Greek market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Construction industry, which is up 13% over the same period.Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total losses of €12.3m, with losses narrowing by 5.0% from the prior year.매출 및 비용 세부 내역Bioter가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이ATSE:BIOT 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비31 Dec 241-2113030 Sep 241-177030 Jun 240-121031 Mar 240-122031 Dec 230-122030 Sep 230-113030 Jun 230-93031 Mar 230-102031 Dec 220-101030 Sep 220-101030 Jun 220-101031 Mar 220-101031 Dec 210-91030 Sep 21001030 Jun 21081031 Mar 21071031 Dec 20061030 Sep 200-21030 Jun 200-111031 Mar 200-101031 Dec 190-91030 Sep 190-111030 Jun 190-131031 Mar 190-131031 Dec 180-131030 Sep 180-151030 Jun 180-181031 Mar 180-181031 Dec 170-181030 Sep 170-181030 Jun 171-181031 Mar 171-181031 Dec 161-181030 Sep 160-161030 Jun 160-101031 Mar 160-101031 Dec 151-101030 Sep 153-142030 Jun 154-142031 Mar 155-122031 Dec 145-142030 Sep 144-1120양질의 수익: BIOT 은(는) 현재 수익성이 없습니다.이익 마진 증가: BIOT는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: BIOT은 수익성이 없으며 지난 5년 동안 손실이 연평균 29.6% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 BIOT의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: BIOT은 수익성이 없어 지난 해 수익 성장률을 Construction 업계(16.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: BIOT의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YCapital-goods 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/08/27 03:59종가2025/05/30 00:00수익2024/12/31연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Bioter S.A.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • May 05Full year 2024 earnings released: €1.27 loss per share (vs €0.70 loss in FY 2023)Full year 2024 results: €1.27 loss per share (further deteriorated from €0.70 loss in FY 2023). Net loss: €21.3m (loss widened 82% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings.
공시 • Apr 28Bioter S.A. to Report Fiscal Year 2023 Results on Apr 29, 2024Bioter S.A. announced that they will report fiscal year 2023 results on Apr 29, 2024
Reported Earnings • Oct 04First half 2022 earnings released: €0.30 loss per share (vs €0.22 loss in 1H 2021)First half 2022 results: €0.30 loss per share (further deteriorated from €0.22 loss in 1H 2021). Net loss: €5.10m (loss widened 38% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth.
분석 기사 • May 06Robust Earnings May Not Tell The Whole Story For Bioter (ATH:BIOT)Bioter S.A.'s ( ATH:BIOT ) robust recent earnings didn't do much to move the stock. We believe that shareholders have...
Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total losses of €12.3m, with losses narrowing by 5.0% from the prior year.
Reported Earnings • May 05Full year 2024 earnings released: €1.27 loss per share (vs €0.70 loss in FY 2023)Full year 2024 results: €1.27 loss per share (further deteriorated from €0.70 loss in FY 2023). Net loss: €21.3m (loss widened 82% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings.
공시 • Apr 30Bioter S.A., Annual General Meeting, Jul 10, 2025Bioter S.A., Annual General Meeting, Jul 10, 2025.
New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.9% average weekly change). Negative equity (-€124m). Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m (€280k revenue, or US$318k). Market cap is less than US$10m (€3.26m market cap, or US$3.70m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
New Risk • Oct 04New major risk - Revenue and earnings growthEarnings have declined by 12% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€11m free cash flow). Share price has been highly volatile over the past 3 months (6.6% average weekly change). Negative equity (-€124m). Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m (€280k revenue, or US$309k). Market cap is less than US$10m (€4.52m market cap, or US$4.98m).
공시 • Apr 28Bioter S.A. to Report Fiscal Year 2023 Results on Apr 29, 2024Bioter S.A. announced that they will report fiscal year 2023 results on Apr 29, 2024
New Risk • Apr 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€112m). Revenue is less than US$1m (€471k revenue, or US$502k). Market cap is less than US$10m (€4.58m market cap, or US$4.88m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).
공시 • Jul 01Bioter S.A., Annual General Meeting, Jul 21, 2023Bioter S.A., Annual General Meeting, Jul 21, 2023, at 09:00 E. Europe Standard Time. Location: 45 Eftichidou str Athens Greece
New Risk • Jul 01New major risk - Revenue and earnings growthRevenue has declined by 17% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€102m). Revenue has declined by 17% over the past year. Revenue is less than US$1m (€241k revenue, or US$263k). Market cap is less than US$10m (€3.51m market cap, or US$3.83m). Minor Risk Latest financial reports are more than 6 months old (reported June 2022 fiscal period end).
Reported Earnings • Oct 04First half 2022 earnings released: €0.30 loss per share (vs €0.22 loss in 1H 2021)First half 2022 results: €0.30 loss per share (further deteriorated from €0.22 loss in 1H 2021). Net loss: €5.10m (loss widened 38% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Sep 01Bioter S.A., Annual General Meeting, Sep 05, 2022Bioter S.A., Annual General Meeting, Sep 05, 2022, at 09:00 E. Europe Standard Time. Location: 45 Eftichidou str Athens Greece
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
분석 기사 • May 06Robust Earnings May Not Tell The Whole Story For Bioter (ATH:BIOT)Bioter S.A.'s ( ATH:BIOT ) robust recent earnings didn't do much to move the stock. We believe that shareholders have...
Is New 90 Day High Low • Jan 04New 90-day high: €0.38The company is up 348% from its price of €0.084 on 06 October 2020. The Greek market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Construction industry, which is up 22% over the same period.
공시 • Jan 02Bioter S.A., Annual General Meeting, Jan 11, 2021Bioter S.A., Annual General Meeting, Jan 11, 2021, at 11:00 E. Europe Standard Time. Location: 45 Eftichidou str. Athens United Kingdom
Is New 90 Day High Low • Dec 16New 90-day high: €0.22The company is up 154% from its price of €0.085 on 17 September 2020. The Greek market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Construction industry, which is up 13% over the same period.
Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total losses of €12.3m, with losses narrowing by 5.0% from the prior year.